Udhayvir S. Grewal, MD, on DLL3: The New Frontier in Extrapulmonary Neuroendocrine Carcinomas

November 19, 2026

Udhayvir S. Grewal, MD, of Emory Winship Cancer Institute, discusses disease biology, classification, and current challenges associated with extrapulmonary neuroendocrine carcinomas (epNEC); the biologic and therapeutic role of DLL3 in these malignancies; how DLL3 is tested for and assessed; and the potential clinical implications of DLL3 expression in epNECs.

Transcript

This video transcript has not been proofread or edited and may contain errors.

Hey, everyone. I am Uday Grewal, a GI and neuroendocrine medical oncologist at the Winship Cancer Institute of Emory University in Atlanta, Georgia, and I'll be talking about DLL 3, the new frontier in neuroendocrine carcinomas. Before we dive in, I think it's important to discuss the classification framework for neuroendocrineoplasms. Neuroendocrineoplasms or NENs are classified based on their uh histomorphology into well differentiated and poorly differentiated. Well differentiated NENs are also referred to as neuroendocrine tumors, which are further classified based on their K 67 proliferation index into grades 12, and 3. Neuroendocrine carcinomas are poorly differentiated neuroendocrine neoplasms, and they are classified into small cell and large cell subtypes based on their appearance under the microscope. By site of origin, these can also be classified as pulmonary necks or extrapulmonary neuroendocrine carcinomas, also abbreviated as EP necks. Talking about the epidemiology of EP necks, you know, often neuroendocrine neoplasms are referred to as rare cancers. We could argue how rare they are, but certainly neuroendocrine carcinomas are relatively rare cancers, and inside of a neuroendocrine carcinoma, the vast majority of these originate in the lung, about more than 91%, and a little less than 9% are actually EP necks, meaning extrapulmonary neuroendocrine carcinomas. This is primarily a disease of older patients, although we're seeing an alarming rise in the incidence of neuroendocrine carcinomas in younger patients, but the median age of diagnosis is about 67 years. 70% of our patients are diagnosed at the metastatic stage, which really speaks to the aggressive nature of this cancer, and about 37% of these patients may have gastroenteroancreatic origin. Talking about the mainstay of treatment, I refuse to use the term standard of care for EPNECs because there really isn't a therapy that will lead to, um, you know, favorable outcomes in these patients. We've considered chemotherapy as a mainstay of treatment in this setting, and largely what we have is extrapolated from small cell lung cancer, which we now know is a completely different entity compared to EPNECs. Looking at retrospective data for first line treatment primarily with carboplatin and toposide, median progression fee survival is about 4.8 months, and median overall survival is about 9 months. When you go to second line treatment, the outcomes are even more sobering, and there isn't really an established second line standard of care. We're looking at median PFS of about 1.8 months and a median overall survival of 4.7 months. There is an emerging target that has gained a lot of traction in this setting, which is DLL 3. What is DLL 3? DLL 3 is delta-like ligand 3, and it is an inhibitory notch ligand. It is expressed in postmitotic cells and works to inhibit the notch pathway, which is an important pathway in neuroendocrine differentiation and is a key driver of neuroendocrine carcinomas. DLL-3 is overexpressed in many neuroendocrine carcinomas, including EP neck, um, with expression varying by site of origin, and approximately 85% of extrapulmonary neuroendocrine carcinomas are DLL-3 positive, and out of those, 50% are considered to be DLL-3 high, which means that their expression levels are greater than 50%. DLL3 testing is primarily performed on immunohistochemistry. Um, there are currently no um FDA approved uh assays for uh testing of DLL3 on immunohistochemistry, but there are several vendors that are now currently offering, and there are also certain assays that are being used on ongoing clinical trials. The bottom line is that this remains sort of a standard modality. For testing of DLL-3. Currently, it is not recommended, um, even in small cell lung cancer, um, as well as extrapulmonary neurocrine carcinomas for patients to undergo, um, testing for DLL-3. Um, in EPNex, that is primarily because there are currently no FDA approved therapies, um, targeting DLL-3. How common is DLL-3 focusing on gastroenteroancreatic neuroendocrine carcinomas. This is a very nicely done study from Memorial Sloan Kettering where they looked at poorly differentiated gastroenteroancreatic neuroendocrine carcinomas and noted that about 71% of these had DLL-3 positivity. And if you look at various sites of origin in Geepnecks, you can see that the range is about 60 to 80%, the highest perhaps in pancreatic neuroendocrine carcinoma. Carcinomas. And if you look at um the expression levels based on the morphology, um, small cell definitely takes the lead, followed by uh neuroendocrine carcinoma not otherwise specified, uh, and then followed by large cell. So, it is um definitely expressed in uh the majority of neuroendocrine carcinomas, and, um, which really makes neuro uh DLL 3 a viable target in this patient population. Now, what, what is really DLL 3 high versus low, um, and this is an emerging concept, especially in uh extrapulmonary neuroendocrine carcinomas. We know uh from uh initial studies uh performed using uh patients screened for the Darian studies that uh in EPNECs, either the DLL 3 expression is very low or very high. So it's kind of like a bimodal uh distribution. And if you put these expression levels on an ROC curve, 50% emerges as a reasonable threshold. So currently that is being used to classify EPNex as DLL-3 high or DLL-3 low. It's important to appreciate that DLL-3 is a versatile target. There are several agents that are currently being studied in ongoing clinical trials, and they're using a diverse array of mechanisms of action. To discuss a few T cell engagers are agents that target DLL-3 as well as CD3 on T cells, and they use this mechanism to then mount immune-mediated cytotoxicity, resulting in tumor kill. This is followed by antibody drug conjugates, or ADCs that deliver intracellular cytotoxic payloads to DLL-3 positive neuroendocrine carcinomas. Then there are radioligand therapies that are delivering radiopharmaceuticals to DLA 3 positive neuroendocrine carcinomas followed by other cellular therapies such as CAR T cell approaches that enable targeted immune mediated tumor killing. So it is really heartening to see that there is such amazing progress being made in this field, and DLL-3 has sort of emerged as a superstar biomarker that has led to the development of a very exciting pipeline of different agents with Diverse mechanisms of action that are currently being investigated for patients with extrapulmonary neuroendocrine carcinoma, which has unfortunately been a static space for the longest time. And finally we have clinical trials and more importantly hope to offer to our patients.

Related Content